STOCK TITAN
  1. Home
  2. Sec-filings
  3. ANET
  4. [Form 4] Arista Networks Insider Trading Activity

[Form 4] Arista Networks Insider Trading Activity

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Schedule 13D/A Amendment 10 highlights: Three related investors—Parag Saxena, Vedanta Partners, LLC and Vedanta Associates, L.P.—updated their beneficial ownership in Reviva Pharmaceuticals Holdings, Inc. (RVPH) as of the event date 27 June 2025 and filing date 1 July 2025.

  • Parag Saxena now reports 6,259,806 shares, or 8.7 % of RVPH’s 68,003,613 outstanding shares. His stake includes 21,400 vested stock options and a mix of common shares, warrants and pre-funded warrants.
  • Vedanta Partners is shown with 5,367,069 shares, equating to 7.5 % of the class.
  • Vedanta Associates reports 3,408,401 shares, or 4.8 %. Because the holding fell below 5 %, Item 5(e) states the entity ceased to be a 5 % beneficial owner on 27 June 2025.
  • No transactions were effected in the past 60 days; changes arise from share count dynamics and warrant/option calculations. Certain warrants are subject to a 4.99 % blocker that limits exercise to avoid crossing ownership thresholds.

Implications for investors: The overall “Vedanta group” remains a significant insider bloc (>8 %) capable of influencing corporate actions. However, one vehicle dropping below 5 % reduces mandatory reporting frequency for that entity and may signal distribution of ownership or passive dilution. The filing contains no operational, financial or strategic updates from RVPH itself.

Punti salienti dell'emendamento 10 al Schedule 13D/A: Tre investitori correlati—Parag Saxena, Vedanta Partners, LLC e Vedanta Associates, L.P.—hanno aggiornato la loro partecipazione azionaria in Reviva Pharmaceuticals Holdings, Inc. (RVPH) alla data dell'evento 27 giugno 2025 e alla data di deposito 1 luglio 2025.

  • Parag Saxena ora detiene 6.259.806 azioni, pari all’8,7% delle 68.003.613 azioni in circolazione di RVPH. La sua partecipazione include 21.400 opzioni azionarie maturate e una combinazione di azioni ordinarie, warrant e warrant prefinanziati.
  • Vedanta Partners risulta con 5.367.069 azioni, equivalenti al 7,5% della categoria.
  • Vedanta Associates dichiara 3.408.401 azioni, pari al 4,8%. Poiché la partecipazione è scesa sotto il 5%, il punto 5(e) indica che l'entità ha cessato di essere un azionista beneficiario del 5% il 27 giugno 2025.
  • Negli ultimi 60 giorni non sono state effettuate transazioni; le variazioni derivano da dinamiche nel conteggio delle azioni e nel calcolo di warrant/opzioni. Alcuni warrant sono soggetti a un blocco del 4,99% che limita l'esercizio per evitare di superare le soglie di proprietà.

Implicazioni per gli investitori: Il gruppo complessivo “Vedanta” rimane un blocco interno significativo (>8%) con capacità di influenzare le azioni societarie. Tuttavia, il calo di una delle entità sotto il 5% riduce la frequenza degli obblighi di comunicazione per quella entità e potrebbe indicare una distribuzione della proprietà o una diluizione passiva. Il deposito non contiene aggiornamenti operativi, finanziari o strategici da parte di RVPH stessa.

Aspectos destacados de la enmienda 10 al Schedule 13D/A: Tres inversores relacionados—Parag Saxena, Vedanta Partners, LLC y Vedanta Associates, L.P.—actualizaron su propiedad beneficiaria en Reviva Pharmaceuticals Holdings, Inc. (RVPH) con fecha del evento 27 de junio de 2025 y fecha de presentación 1 de julio de 2025.

  • Parag Saxena reporta ahora 6,259,806 acciones, equivalentes al 8.7% de las 68,003,613 acciones en circulación de RVPH. Su participación incluye 21,400 opciones de acciones ya adquiridas y una combinación de acciones comunes, warrants y warrants prefinanciados.
  • Vedanta Partners aparece con 5,367,069 acciones, que representan el 7.5% de la clase.
  • Vedanta Associates reporta 3,408,401 acciones, o el 4.8%. Debido a que la participación cayó por debajo del 5%, el punto 5(e) indica que la entidad dejó de ser un propietario beneficiario del 5% el 27 de junio de 2025.
  • No se realizaron transacciones en los últimos 60 días; los cambios provienen de dinámicas en el conteo de acciones y cálculos de warrants/opciones. Algunos warrants están sujetos a un bloqueo del 4.99% que limita su ejercicio para evitar superar los umbrales de propiedad.

Implicaciones para los inversores: El grupo “Vedanta” en conjunto sigue siendo un bloque interno significativo (>8%) capaz de influir en las acciones corporativas. Sin embargo, que una entidad baje del 5% reduce la frecuencia de los informes obligatorios para esa entidad y puede indicar una distribución de la propiedad o una dilución pasiva. La presentación no contiene actualizaciones operativas, financieras o estratégicas de RVPH.

Schedule 13D/A 수정안 10의 주요 내용: 세 명의 관련 투자자—Parag Saxena, Vedanta Partners, LLC, 그리고 Vedanta Associates, L.P.—가 2025년 6월 27일 기준 및 2025년 7월 1일 제출일자로 Reviva Pharmaceuticals Holdings, Inc. (RVPH)의 실질 소유 지분을 갱신했습니다.

  • Parag Saxena는 현재 RVPH의 총 68,003,613주 중 6,259,806주, 즉 8.7%를 보유하고 있습니다. 그의 지분에는 21,400주의 행사 가능한 스톡옵션과 보통주, 워런트, 선지급 워런트가 혼합되어 있습니다.
  • Vedanta Partners는 5,367,069주로, 전체 주식의 7.5%를 차지합니다.
  • Vedanta Associates는 3,408,401주를 보유하여 4.8%를 차지합니다. 보유 지분이 5% 미만으로 떨어짐에 따라 5(e)항에 따르면 해당 법인은 2025년 6월 27일부로 5% 이상의 실질 소유주 지위를 상실했습니다.
  • 최근 60일간 거래는 없었으며, 변동은 주식 수 변화와 워런트/옵션 계산에 따른 것입니다. 일부 워런트는 소유 지분 한도를 초과하지 않도록 4.99%의 차단 장치가 적용되어 행사 제한이 있습니다.

투자자에 대한 시사점: 전체 “Vedanta 그룹”은 여전히 8% 이상으로 중요한 내부자 그룹으로서 기업 활동에 영향을 미칠 수 있습니다. 다만, 한 법인의 보유 지분이 5% 미만으로 떨어지면서 해당 법인의 의무 보고 빈도가 줄어들고, 지분 분산 또는 수동적 희석 가능성을 시사할 수 있습니다. 제출 서류에는 RVPH 자체의 운영, 재무 또는 전략적 업데이트는 포함되어 있지 않습니다.

Points clés de l’amendement 10 au Schedule 13D/A : Trois investisseurs liés—Parag Saxena, Vedanta Partners, LLC et Vedanta Associates, L.P.—ont mis à jour leur propriété bénéficiaire dans Reviva Pharmaceuticals Holdings, Inc. (RVPH) à la date de l’événement du 27 juin 2025 et à la date de dépôt du 1er juillet 2025.

  • Parag Saxena déclare désormais 6 259 806 actions, soit 8,7 % des 68 003 613 actions en circulation de RVPH. Sa participation comprend 21 400 options d’achat d’actions acquises et un mélange d’actions ordinaires, de bons de souscription et de bons de souscription préfinancés.
  • Vedanta Partners est indiqué avec 5 367 069 actions, représentant 7,5 % de la catégorie.
  • Vedanta Associates déclare 3 408 401 actions, soit 4,8 %. Étant donné que la détention est passée sous la barre des 5 %, l’article 5(e) précise que l’entité a cessé d’être un propriétaire bénéficiaire à 5 % le 27 juin 2025.
  • Aucune transaction n’a été effectuée au cours des 60 derniers jours ; les changements résultent de la dynamique du nombre d’actions et du calcul des bons/options. Certains bons sont soumis à un verrouillage à 4,99 % qui limite leur exercice afin d’éviter de dépasser les seuils de propriété.

Implications pour les investisseurs : Le « groupe Vedanta » dans son ensemble reste un bloc d’initiés important (>8 %) capable d’influencer les actions de la société. Toutefois, la baisse d’une entité sous 5 % réduit la fréquence des obligations de déclaration pour cette entité et peut indiquer une répartition de la propriété ou une dilution passive. Le dépôt ne contient aucune mise à jour opérationnelle, financière ou stratégique de la part de RVPH elle-même.

Wesentliche Punkte der Änderung 10 zum Schedule 13D/A: Drei verbundene Investoren—Parag Saxena, Vedanta Partners, LLC und Vedanta Associates, L.P.—haben ihre wirtschaftliche Eigentümerschaft an Reviva Pharmaceuticals Holdings, Inc. (RVPH) zum Ereignisdatum 27. Juni 2025 und Einreichungsdatum 1. Juli 2025 aktualisiert.

  • Parag Saxena meldet nun 6.259.806 Aktien, das entspricht 8,7 % der 68.003.613 ausstehenden Aktien von RVPH. Sein Anteil umfasst 21.400 ausgeübte Aktienoptionen sowie eine Mischung aus Stammaktien, Warrants und vorfinanzierten Warrants.
  • Vedanta Partners wird mit 5.367.069 Aktien geführt, was 7,5 % der Klasse entspricht.
  • Vedanta Associates berichtet 3.408.401 Aktien, also 4,8 %. Da der Anteil unter 5 % gefallen ist, gibt Punkt 5(e) an, dass die Einheit am 27. Juni 2025 keine 5-%-Beteiligung mehr hält.
  • In den letzten 60 Tagen wurden keine Transaktionen durchgeführt; Änderungen ergeben sich aus der Dynamik der Aktienanzahl und der Berechnung von Warrants/Optionen. Einige Warrants unterliegen einer 4,99-%-Blockade, die die Ausübung einschränkt, um eine Überschreitung der Eigentumsschwellen zu vermeiden.

Auswirkungen für Investoren: Die gesamte „Vedanta-Gruppe“ bleibt ein bedeutender Insiderblock (>8 %), der in der Lage ist, Unternehmensentscheidungen zu beeinflussen. Allerdings verringert das Unterschreiten der 5-%-Marke durch eine Einheit die Häufigkeit der Meldepflichten für diese Einheit und kann auf eine Verteilung der Eigentumsverhältnisse oder passive Verwässerung hinweisen. Die Einreichung enthält keine operativen, finanziellen oder strategischen Updates von RVPH selbst.

Positive
  • Continued significant insider ownership—Parag Saxena holds 8.7 %, suggesting ongoing commitment to RVPH.
  • No recent insider sales reported, implying stability in the shareholder base.
Negative
  • Vedanta Associates' stake fell below 5 %, potentially signaling dilution or partial exit.
  • Minor discrepancy between 6,259,806 and 6,269,806 share counts within the filing, which could cause confusion.

Insights

TL;DR — Insider group still strong; one fund dips below 5 %.

The amendment primarily refreshes ownership data. Saxena and related funds collectively continue to own a meaningful 8-9 % stake, maintaining influence and signalling ongoing confidence. Vedanta Associates’ drop to 4.8 % removes it from 5 %-plus disclosure status, but group control is essentially unchanged. No share sales are disclosed over the last 60 days, so the percentage shift is most likely dilution-driven rather than a disposal. From a valuation perspective the filing is neutral; it neither injects capital nor alters fundamentals, yet it reassures that a long-term insider remains committed.

TL;DR — Governance impact minor; reporting compliance intact.

The amendment satisfies Section 13(d) obligations after a threshold change. While Vedanta Associates exits the >5 % bracket, Saxena still files as a control person. Investors should note the 4.99 % blocker on certain warrants, limiting sudden voting power spikes. No coordinated “group” box was ticked, reducing takeover-speculation risk. Overall governance impact is limited and does not trigger anti-dilution or poison-pill provisions.

Punti salienti dell'emendamento 10 al Schedule 13D/A: Tre investitori correlati—Parag Saxena, Vedanta Partners, LLC e Vedanta Associates, L.P.—hanno aggiornato la loro partecipazione azionaria in Reviva Pharmaceuticals Holdings, Inc. (RVPH) alla data dell'evento 27 giugno 2025 e alla data di deposito 1 luglio 2025.

  • Parag Saxena ora detiene 6.259.806 azioni, pari all’8,7% delle 68.003.613 azioni in circolazione di RVPH. La sua partecipazione include 21.400 opzioni azionarie maturate e una combinazione di azioni ordinarie, warrant e warrant prefinanziati.
  • Vedanta Partners risulta con 5.367.069 azioni, equivalenti al 7,5% della categoria.
  • Vedanta Associates dichiara 3.408.401 azioni, pari al 4,8%. Poiché la partecipazione è scesa sotto il 5%, il punto 5(e) indica che l'entità ha cessato di essere un azionista beneficiario del 5% il 27 giugno 2025.
  • Negli ultimi 60 giorni non sono state effettuate transazioni; le variazioni derivano da dinamiche nel conteggio delle azioni e nel calcolo di warrant/opzioni. Alcuni warrant sono soggetti a un blocco del 4,99% che limita l'esercizio per evitare di superare le soglie di proprietà.

Implicazioni per gli investitori: Il gruppo complessivo “Vedanta” rimane un blocco interno significativo (>8%) con capacità di influenzare le azioni societarie. Tuttavia, il calo di una delle entità sotto il 5% riduce la frequenza degli obblighi di comunicazione per quella entità e potrebbe indicare una distribuzione della proprietà o una diluizione passiva. Il deposito non contiene aggiornamenti operativi, finanziari o strategici da parte di RVPH stessa.

Aspectos destacados de la enmienda 10 al Schedule 13D/A: Tres inversores relacionados—Parag Saxena, Vedanta Partners, LLC y Vedanta Associates, L.P.—actualizaron su propiedad beneficiaria en Reviva Pharmaceuticals Holdings, Inc. (RVPH) con fecha del evento 27 de junio de 2025 y fecha de presentación 1 de julio de 2025.

  • Parag Saxena reporta ahora 6,259,806 acciones, equivalentes al 8.7% de las 68,003,613 acciones en circulación de RVPH. Su participación incluye 21,400 opciones de acciones ya adquiridas y una combinación de acciones comunes, warrants y warrants prefinanciados.
  • Vedanta Partners aparece con 5,367,069 acciones, que representan el 7.5% de la clase.
  • Vedanta Associates reporta 3,408,401 acciones, o el 4.8%. Debido a que la participación cayó por debajo del 5%, el punto 5(e) indica que la entidad dejó de ser un propietario beneficiario del 5% el 27 de junio de 2025.
  • No se realizaron transacciones en los últimos 60 días; los cambios provienen de dinámicas en el conteo de acciones y cálculos de warrants/opciones. Algunos warrants están sujetos a un bloqueo del 4.99% que limita su ejercicio para evitar superar los umbrales de propiedad.

Implicaciones para los inversores: El grupo “Vedanta” en conjunto sigue siendo un bloque interno significativo (>8%) capaz de influir en las acciones corporativas. Sin embargo, que una entidad baje del 5% reduce la frecuencia de los informes obligatorios para esa entidad y puede indicar una distribución de la propiedad o una dilución pasiva. La presentación no contiene actualizaciones operativas, financieras o estratégicas de RVPH.

Schedule 13D/A 수정안 10의 주요 내용: 세 명의 관련 투자자—Parag Saxena, Vedanta Partners, LLC, 그리고 Vedanta Associates, L.P.—가 2025년 6월 27일 기준 및 2025년 7월 1일 제출일자로 Reviva Pharmaceuticals Holdings, Inc. (RVPH)의 실질 소유 지분을 갱신했습니다.

  • Parag Saxena는 현재 RVPH의 총 68,003,613주 중 6,259,806주, 즉 8.7%를 보유하고 있습니다. 그의 지분에는 21,400주의 행사 가능한 스톡옵션과 보통주, 워런트, 선지급 워런트가 혼합되어 있습니다.
  • Vedanta Partners는 5,367,069주로, 전체 주식의 7.5%를 차지합니다.
  • Vedanta Associates는 3,408,401주를 보유하여 4.8%를 차지합니다. 보유 지분이 5% 미만으로 떨어짐에 따라 5(e)항에 따르면 해당 법인은 2025년 6월 27일부로 5% 이상의 실질 소유주 지위를 상실했습니다.
  • 최근 60일간 거래는 없었으며, 변동은 주식 수 변화와 워런트/옵션 계산에 따른 것입니다. 일부 워런트는 소유 지분 한도를 초과하지 않도록 4.99%의 차단 장치가 적용되어 행사 제한이 있습니다.

투자자에 대한 시사점: 전체 “Vedanta 그룹”은 여전히 8% 이상으로 중요한 내부자 그룹으로서 기업 활동에 영향을 미칠 수 있습니다. 다만, 한 법인의 보유 지분이 5% 미만으로 떨어지면서 해당 법인의 의무 보고 빈도가 줄어들고, 지분 분산 또는 수동적 희석 가능성을 시사할 수 있습니다. 제출 서류에는 RVPH 자체의 운영, 재무 또는 전략적 업데이트는 포함되어 있지 않습니다.

Points clés de l’amendement 10 au Schedule 13D/A : Trois investisseurs liés—Parag Saxena, Vedanta Partners, LLC et Vedanta Associates, L.P.—ont mis à jour leur propriété bénéficiaire dans Reviva Pharmaceuticals Holdings, Inc. (RVPH) à la date de l’événement du 27 juin 2025 et à la date de dépôt du 1er juillet 2025.

  • Parag Saxena déclare désormais 6 259 806 actions, soit 8,7 % des 68 003 613 actions en circulation de RVPH. Sa participation comprend 21 400 options d’achat d’actions acquises et un mélange d’actions ordinaires, de bons de souscription et de bons de souscription préfinancés.
  • Vedanta Partners est indiqué avec 5 367 069 actions, représentant 7,5 % de la catégorie.
  • Vedanta Associates déclare 3 408 401 actions, soit 4,8 %. Étant donné que la détention est passée sous la barre des 5 %, l’article 5(e) précise que l’entité a cessé d’être un propriétaire bénéficiaire à 5 % le 27 juin 2025.
  • Aucune transaction n’a été effectuée au cours des 60 derniers jours ; les changements résultent de la dynamique du nombre d’actions et du calcul des bons/options. Certains bons sont soumis à un verrouillage à 4,99 % qui limite leur exercice afin d’éviter de dépasser les seuils de propriété.

Implications pour les investisseurs : Le « groupe Vedanta » dans son ensemble reste un bloc d’initiés important (>8 %) capable d’influencer les actions de la société. Toutefois, la baisse d’une entité sous 5 % réduit la fréquence des obligations de déclaration pour cette entité et peut indiquer une répartition de la propriété ou une dilution passive. Le dépôt ne contient aucune mise à jour opérationnelle, financière ou stratégique de la part de RVPH elle-même.

Wesentliche Punkte der Änderung 10 zum Schedule 13D/A: Drei verbundene Investoren—Parag Saxena, Vedanta Partners, LLC und Vedanta Associates, L.P.—haben ihre wirtschaftliche Eigentümerschaft an Reviva Pharmaceuticals Holdings, Inc. (RVPH) zum Ereignisdatum 27. Juni 2025 und Einreichungsdatum 1. Juli 2025 aktualisiert.

  • Parag Saxena meldet nun 6.259.806 Aktien, das entspricht 8,7 % der 68.003.613 ausstehenden Aktien von RVPH. Sein Anteil umfasst 21.400 ausgeübte Aktienoptionen sowie eine Mischung aus Stammaktien, Warrants und vorfinanzierten Warrants.
  • Vedanta Partners wird mit 5.367.069 Aktien geführt, was 7,5 % der Klasse entspricht.
  • Vedanta Associates berichtet 3.408.401 Aktien, also 4,8 %. Da der Anteil unter 5 % gefallen ist, gibt Punkt 5(e) an, dass die Einheit am 27. Juni 2025 keine 5-%-Beteiligung mehr hält.
  • In den letzten 60 Tagen wurden keine Transaktionen durchgeführt; Änderungen ergeben sich aus der Dynamik der Aktienanzahl und der Berechnung von Warrants/Optionen. Einige Warrants unterliegen einer 4,99-%-Blockade, die die Ausübung einschränkt, um eine Überschreitung der Eigentumsschwellen zu vermeiden.

Auswirkungen für Investoren: Die gesamte „Vedanta-Gruppe“ bleibt ein bedeutender Insiderblock (>8 %), der in der Lage ist, Unternehmensentscheidungen zu beeinflussen. Allerdings verringert das Unterschreiten der 5-%-Marke durch eine Einheit die Häufigkeit der Meldepflichten für diese Einheit und kann auf eine Verteilung der Eigentumsverhältnisse oder passive Verwässerung hinweisen. Die Einreichung enthält keine operativen, finanziellen oder strategischen Updates von RVPH selbst.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ullal Jayshree
(Last) (First) (Middle)
5453 GREAT AMERICA PARKWAY
(Street)
SANTA CLARA CA 95054
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Arista Networks, Inc. [ ANET ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
3. Date of Earliest Transaction (Month/Day/Year)
06/27/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/27/2025 S(1) 223 D $101.9921(2) 103,385 D
Common Stock 06/27/2025 S(1) 241 D $101.9921(2) 6,368,849 I By Trust for Child 1(3)
Common Stock 06/27/2025 S(1) 241 D $101.9921(2) 6,368,849 I By Trust for Child 2(3)
Common Stock 06/27/2025 S(1) 20 D $101.9921(2) 38,756 I By Trust for Nephew(4)
Common Stock 06/27/2025 S(1) 20 D $101.9921(2) 38,756 I By Trust for Niece(4)
Common Stock 06/27/2025 S(1) 1,271 D $101.9921(2) 24,418,658 I by Trust(5)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The exercises and/or sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2024.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.99 to $102.00, inclusive. The reporting person undertakes to provide Arista Networks, Inc., any security holder of Arista Networks, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. These shares are held in trust for the benefit of the children of the reporting person for which the reporting person serves as trustee. The reporting person shares voting and investment control over the shares but disclaims beneficial ownership of the shares.
4. These shares are held in trust for the benefit of relatives of the reporting person for which the reporting person serves as co-trustee. The reporting person shares voting and investment control over the shares but disclaims beneficial ownership of the shares.
5. These shares are held by a family trust for which the reporting person is co-trustee.
By: Isabelle Bertin-Bailly, Attorney-in-Fact For: Jayshree Ullal 07/01/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

How much of RVPH does Parag Saxena currently own?

The filing cites 6,259,806 shares, representing 8.7 % of Reviva’s common stock.

Which Vedanta entity fell below the 5 % ownership threshold in RVPH?

Vedanta Associates, L.P. dropped to 4.8 % and is no longer a 5 % beneficial owner as of 27 June 2025.

Do the reporting persons disclose any recent transactions in RVPH shares?

No. Item 5(c) confirms no transactions in the past 60 days.

What is the significance of the 4.99 % blocker mentioned in the filing?

Certain warrants cannot be exercised if doing so would push ownership above 4.99 %, limiting immediate voting power increases.

What percentage of RVPH is held by Vedanta Partners, LLC?

Vedanta Partners reports 5,367,069 shares, equal to 7.5 % of outstanding common stock.
Stock ANET logo
Arista Networks Inc

NYSE:ANET

ANET Rankings

#158 Ranked by Market Cap
N/A Ranked by Dividends

ANET Latest News

Jul 8, 2025
Arista Networks to Announce Q2 2025 Financial Results on Tuesday, August 5, 2025
Jul 1, 2025
Arista Networks Expands AI-Driven Campus and Branch Networking Offerings
May 6, 2025
Arista Networks, Inc. Reports First Quarter 2025 Financial Results
Apr 8, 2025
Arista Networks to Announce Q1 2025 Financial Results on Tuesday, May 6, 2025
Mar 12, 2025
Arista Introduces Intelligent Innovations for AI Networking

ANET Latest SEC Filings

Jul 15, 2025
[Form 4] Arista Networks Insider Trading Activity
Jul 11, 2025
[Form 3] Arista Networks Initial Statement of Beneficial Ownership
Jul 3, 2025
[Form 4] Arista Networks Insider Trading Activity
Jul 2, 2025
[Form 4] Arista Networks Insider Trading Activity
Jun 30, 2025
[Form 4] Arista Networks Insider Trading Activity

ANET Stock Data

129.85B
1.03B
18.16%
68.58%
1.21%
Computer Hardware
Computer Communications Equipment
Link
United States
SANTA CLARA